Molecure reports accelerated progress in clinical and preclinical programs for 2023

2024-04-03

临床2期临床1期

The company wantd to share some of its highlights and significant advancements in both clinical and preclinical programs. The company aims to continue its momentum into 2024 and 2025 with robust research initiatives.

In a statement, Marcin Szumowski, CEO of Molecure S.A., emphasized the exceptional progress made during 2023.

“Last year was an exceptional year for Molecure as we made significant progress in the development of both clinical and preclinical programmes, particularly in the area of small-molecule drugs targeting mRNA,” said Szumowski.

Key highlights from Molecure's 2023 annual report include a phase 2 clinical trial initiation for OATD-01 (KITE). This saw Molecure receive approval from both the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a phase 2 clinical trial for OATD-01, a groundbreaking drug candidate for the treatment of pulmonary sarcoidosis. The first patient has already begun dosing in a clinical trial in the UK, marking a significant milestone in Molecure's flagship clinical program.

Advancements were also made with mRNA platform development where Molecure achieved a major breakthrough in mRNA platform development by successfully inhibiting the translation of pathogenic proteins in a cellular assay, demonstrating the platform's potential in targeting mRNA for therapeutic purposes.

There was progress in the OATD-02 phase 1 clinical trial and the company made further strides in the phase 1 clinical trial of OATD-02, a dual arginase inhibitor designed for cancer treatment. Systematic dose escalation and progression to a fourth cohort of patients with solid tumors were achieved, aiming to determine the maximum tolerated dose and recommended dose for subsequent trials.

googletag.cmd.push(function () {

googletag.display('text-ad1');

});

Preclinical development of USP7 Inhibitor USP7 Inhibitor Program - Molecure continued to advance its most promising project in the preclinical phase, focusing on the USP7 inhibitor USP7 inhibitor program for anti-cancer therapies. The company utilized artificial intelligence tools and models to drive progress in this area.

Szumowski also addressed the challenges faced by biotech companies in recent years, including geopolitical instability, inflation, and fluctuating interest rates. Despite these obstacles, Molecure successfully completed a capital round, raising approximately PLN 50 million in growth funding through a share issue. The company remains committed to its mission of delivering innovative treatments to patients while providing significant returns to shareholders.

“We are confident that pursuing our mission will open up new treatment opportunities for patients and provide a significant return on investment for shareholders,” said Szumowski.

“We thank you for your trust to date and encourage you to continue working with us.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构